Intervention

T-DM1

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 27 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials27
Recruiting4
Common conditions24
Lead sponsors shown15
Advertisement

Clinical trials

27 shown
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapyNCT06830889 · 2025-06-03
RECRUITING
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerNCT07673029 · 2025-01-10
RECRUITING
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerNCT06439693 · 2024-08-08
RECRUITING
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerNCT05288777 · 2022-07-11
RECRUITING
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerNCT06316531 · 2024-05-08
ACTIVE_NOT_RECRUITING
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerNCT06265428 · 2024-01-29
ACTIVE_NOT_RECRUITING
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyNCT06968585 · 2023-07-18
ACTIVE_NOT_RECRUITING
Precise Therapy for Refractory HER2 Positive Advanced Breast CancerNCT05429684 · 2021-01-01
UNKNOWN
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · 2020-12-04
ACTIVE_NOT_RECRUITING
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerNCT04398914 · 2020-05-30
ACTIVE_NOT_RECRUITING
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneNCT04158947 · 2020-05-10
UNKNOWN
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647 · 2019-10-02
ACTIVE_NOT_RECRUITING
T-DM1 and Palbociclib for Metastatic HER2 Breast CancerNCT03530696 · 2018-12-06
COMPLETED
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerNCT03709082 · 2018-10-15
TERMINATED
ATOP TRIAL: T-DM1 in HER2 Positive Breast CancerNCT03587740 · 2018-08-22
ACTIVE_NOT_RECRUITING
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerNCT03429101 · 2018-07-13
TERMINATED
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic RadiosurgeryNCT03190967 · 2018-04-18
TERMINATED
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1NCT03032107 · 2017-02-17
COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.NCT02657343 · 2016-03-09
COMPLETED
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCANCT02326974 · 2015-01-01
ACTIVE_NOT_RECRUITING
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerNCT02236000 · 2014-08-01
COMPLETED
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerNCT01983501 · 2014-02-28
COMPLETED
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelNCT02073487 · 2014-02-01
COMPLETED
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerNCT02073916 · 2013-10-01
COMPLETED
Trastuzumab & Pertuzumab Followed by T-DM1 in MBCNCT01835236 · 2013-03-03
COMPLETED
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.NCT01745965 · 2012-11-01
COMPLETED
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1NCT01565200 · 2012-05-01
COMPLETED

Common conditions

Breast Cancer12HER2-positive Breast Cancer10Metastatic Breast Cancer3Breast Cancer Metastatic2HER-2 Positive Breast Cancer2Brain Cancer1Brain Metastases1Brain Metastasis1Breast Cancer Female1Breast Cancer Invasive1Breast Cancer Stage1Breast Cancer Stage I1Breast Cancer Stage II1Breast Cancer Stage III1Estrogen Receptor-positive Breast Cancer1HER2 Positive Breast Cancers1HER2 Positive Breast Carcinoma1HER2-Positive Primary Breast Cancer1HER2+ Breast Cancer1Recurrent Breast Cancer1Residual Invasive Breast Cancer1Stage II Breast Cancer1Stage III Breast Cancer1Stage IV Breast Cancer1

Trial status mix

COMPLETED10
ACTIVE_NOT_RECRUITING8
RECRUITING4
TERMINATED3
UNKNOWN2

Phase mix

PHASE215
PHASE39
PHASE18
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.